Literature DB >> 34299074

In Vitro and In Silico Characterization of an Antimalarial Compound with Antitumor Activity Targeting Human DNA Topoisomerase IB.

Bini Chhetri Soren1, Jagadish Babu Dasari1, Alessio Ottaviani1, Beatrice Messina1, Giada Andreotti1, Alice Romeo1, Federico Iacovelli1, Mattia Falconi1, Alessandro Desideri1, Paola Fiorani1,2.   

Abstract

Human DNA topoisomerase IB controls the topological state of supercoiled DNA through a complex catalytic cycle that consists of cleavage and religation reactions, allowing the progression of fundamental DNA metabolism. The catalytic steps of human DNA topoisomerase IB were analyzed in the presence of a drug, obtained by the open-access drug bank Medicines for Malaria Venture. The experiments indicate that the compound strongly and irreversibly inhibits the cleavage step of the enzyme reaction and reduces the cell viability of three different cancer cell lines. Molecular docking and molecular dynamics simulations suggest that the drug binds to the human DNA topoisomerase IB-DNA complex sitting inside the catalytic site of the enzyme, providing a molecular explanation for the cleavage-inhibition effect. For all these reasons, the aforementioned drug could be a possible lead compound for the development of an efficient anti-tumor molecule targeting human DNA topoisomerase IB.

Entities:  

Keywords:  cancer; drug; human DNA topoisomerase; molecular docking

Year:  2021        PMID: 34299074     DOI: 10.3390/ijms22147455

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  2 in total

1.  Novel Strategies in the Development of New Therapies, Drug Substances, and Drug Carriers Volume I.

Authors:  Andrzej Kutner; Geoffrey Brown; Enikö Kallay
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

2.  From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge Dendrilla antarctica.

Authors:  Alessio Ottaviani; Joshua Welsch; Keli Agama; Yves Pommier; Alessandro Desideri; Bill J Baker; Paola Fiorani
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.